[8-K] Stewart Information Services Corporation Reports Material Event
Elevation Oncology (ELEV) filed five Post-Effective Amendments to prior Form S-8 registration statements to deregister all unsold shares tied to its 2019 Stock Incentive Plan, 2021 Equity Incentive Plan and 2021 ESPP. The move follows the 23 Jul 2025 closing of the merger with Concentra Biosciences, after which Elevation became a wholly owned subsidiary and its public offerings ceased.
Under the merger each common share was converted into $0.36 in cash plus one non-transferable contingent value right (CVR). Approximately 14.3 million shares鈥攁bout 9.7 m under the 2021 Plan, 1.7 m under the ESPP and 2.4 m under the 2019 Plan鈥攁re being withdrawn from registration. The filing removes any future equity issuance from these plans and formally ends the company鈥檚 S-8 reporting obligations.
Elevation Oncology (ELEV) ha presentato cinque Emendamenti Post-Efficaci a precedenti dichiarazioni di registrazione Form S-8 per cancellare la registrazione di tutte le azioni invendute relative al suo Piano di Incentivi Azionari 2019, al Piano di Incentivi Azionari 2021 e al Piano di Acquisto Azionario per Dipendenti (ESPP) 2021. Questa azione segue la chiusura della fusione del 23 luglio 2025 con Concentra Biosciences, dopo la quale Elevation 猫 diventata una controllata interamente posseduta e le sue offerte pubbliche sono cessate.
In base alla fusione, ogni azione ordinaria 猫 stata convertita in 0,36 $ in contanti pi霉 un diritto contingente di valore non trasferibile (CVR). Circa 14,3 milioni di azioni鈥攃irca 9,7 milioni sotto il Piano 2021, 1,7 milioni sotto l'ESPP e 2,4 milioni sotto il Piano 2019鈥攕ono state ritirate dalla registrazione. La presentazione elimina qualsiasi futura emissione di azioni da questi piani e conclude formalmente gli obblighi di rendicontazione S-8 della societ脿.
Elevation Oncology (ELEV) present贸 cinco Enmiendas Post-Efectivas a declaraciones de registro Form S-8 previas para cancelar la inscripci贸n de todas las acciones no vendidas relacionadas con su Plan de Incentivos de Acciones 2019, Plan de Incentivos de Acciones 2021 y Plan de Compra de Acciones para Empleados (ESPP) 2021. Esta acci贸n sigue al cierre de la fusi贸n el 23 de julio de 2025 con Concentra Biosciences, tras lo cual Elevation se convirti贸 en una subsidiaria de propiedad total y cesaron sus ofertas p煤blicas.
Bajo la fusi贸n, cada acci贸n com煤n se convirti贸 en
Elevation Oncology (ELEV)電� 2019雲� 欤检嫕 鞚胳劶韹半笇 頂岆灉, 2021雲� 欤检嫕 鞚胳劶韹半笇 頂岆灉 氚� 2021雲� ESPP鞕� 甏�霠悳 氙疙寪毵� 欤检嫕 鞝勲秬毳� 霌彪 毵愳唽頃橁赴 鞙勴暣 鞚挫爠 Form S-8 霌彪 鞁犼碃靹滌棎 雽�頃� 雼れ劘 瓯挫潣 靷泟 須牓 靾橃爼靹滊ゼ 鞝滌稖頄堨姷雼堧嫟. 鞚� 臁办箻電� 2025雲� 7鞗� 23鞚� Concentra Biosciences鞕�鞚� 頃╇硲 膦呺鞐� 霐半ジ 瓴冹溂搿�, 鞚错泟 Elevation鞚� 鞕勳爠 鞛愴殞靷 鞝勴櫂霅橃柎 瓿店皽 欤检嫕 氚滍枆鞚� 欷戨嫧霅橃棃鞀惦媹雼�.
頃╇硲鞐� 霐半澕 氤错喌欤茧姅 欤茧嫻 順勱笀 0.36雼煬鞕� 鞏戨弰 攵堦皜電ロ暅 臁瓣贝攵� 臧�旃� 甓岆Μ(CVR) 1臧�搿� 鞝勴櫂霅橃棃鞀惦媹雼�. 鞎� 1,430毵� 欤�鈥�2021雲� 頂岆灉鞐愳劀 鞎� 970毵� 欤�, ESPP鞐愳劀 170毵� 欤�, 2019雲� 頂岆灉鞐愳劀 240毵� 欤尖�旉皜 霌彪鞐愳劀 觳犿殞霅橁碃 鞛堨姷雼堧嫟. 鞚措矆 鞝滌稖搿� 鞚措摛 頂岆灉鞐愳劀鞚� 頄ロ泟 欤检嫕 氚滍枆鞚� 欷戨嫧霅橁碃 須岇偓鞚� S-8 氤搓碃 鞚橂臧� 瓿奠嫕鞝侅溂搿� 膦呺霅╇媹雼�.
Elevation Oncology (ELEV) a d茅pos茅 cinq amendements post-efficacit茅 aux d茅clarations d鈥檈nregistrement Form S-8 ant茅rieures afin de d茅r茅f茅rencer toutes les actions invendues li茅es 脿 son Plan d鈥橧ncentive Actions 2019, au Plan d鈥橧ncentive Actions 2021 et au Plan d鈥橝chat d鈥橝ctions des Employ茅s (ESPP) 2021. Cette d茅marche fait suite 脿 la cl么ture de la fusion le 23 juillet 2025 avec Concentra Biosciences, apr猫s laquelle Elevation est devenue une filiale en propri茅t茅 exclusive et ses offres publiques ont cess茅.
Dans le cadre de la fusion, chaque action ordinaire a 茅t茅 convertie en 0,36 $ en esp猫ces plus un droit de valeur conditionnel non transf茅rable (CVR). Environ 14,3 millions d鈥檃ctions鈥攅nviron 9,7 millions sous le Plan 2021, 1,7 million sous l鈥橢SPP et 2,4 millions sous le Plan 2019鈥攕ont retir茅es de l鈥檈nregistrement. Ce d茅p么t supprime toute 茅mission future d鈥檃ctions issues de ces plans et met officiellement fin aux obligations de reporting S-8 de la soci茅t茅.
Elevation Oncology (ELEV) hat f眉nf Nachwirkende 脛nderungen zu fr眉heren Form S-8-Registrierungserkl盲rungen eingereicht, um alle unver盲u脽erten Aktien im Zusammenhang mit dem Aktienanreizplan 2019, dem Aktienanreizplan 2021 und dem Aktienkaufplan f眉r Mitarbeiter (ESPP) 2021 abzumelden. Dieser Schritt folgt auf den Abschluss der Fusion am 23. Juli 2025 mit Concentra Biosciences, nach der Elevation eine hundertprozentige Tochtergesellschaft wurde und 枚ffentliche Angebote eingestellt wurden.
Im Rahmen der Fusion wurde jede Stammaktie in 0,36 $ in bar plus ein nicht 眉bertragbares bedingtes Wertrecht (CVR) umgewandelt. Etwa 14,3 Millionen Aktien鈥攄avon etwa 9,7 Mio. unter dem 2021er Plan, 1,7 Mio. unter dem ESPP und 2,4 Mio. unter dem 2019er Plan鈥攚erden aus der Registrierung zur眉ckgezogen. Die Einreichung verhindert k眉nftige Aktienausgaben aus diesen Pl盲nen und beendet formell die S-8-Berichtspflichten des Unternehmens.
- Completion of merger provides shareholders $0.36 cash plus a CVR per share.
- Deregistration of ~14.3 m shares eliminates potential post-merger dilution.
- Low cash consideration ($0.36) highlights weak standalone valuation for Elevation Oncology.
- Termination of equity incentive and ESPP plans removes stock-based compensation, potentially impacting employee retention.
Insights
TL;DR: Purely administrative S-8 deregistration after merger; no new economic terms disclosed; dilution risk eliminated.
Deregistering unsold shares is standard once a target goes private. All equity plans are void, so the roughly 14 m shares can no longer hit the float鈥攎arginally positive for dilution, but the stock is already cashed out at $0.36 with a CVR. Impact on current public investors is moot because the security is no longer listed. No new consideration, synergies or financials are provided; therefore, market impact is neutral.
TL;DR: Filing fulfills Rule 478 undertaking, cleans up SEC records, ends incentive plans.
By terminating its S-8s, Elevation meets post-merger compliance and removes residual employee option pools. This limits future governance complexity for the parent company, but may affect employee retention as legacy equity incentives disappear. Because the merger terms were finalized earlier, today鈥檚 action is procedural and carries negligible incremental financial impact.
Elevation Oncology (ELEV) ha presentato cinque Emendamenti Post-Efficaci a precedenti dichiarazioni di registrazione Form S-8 per cancellare la registrazione di tutte le azioni invendute relative al suo Piano di Incentivi Azionari 2019, al Piano di Incentivi Azionari 2021 e al Piano di Acquisto Azionario per Dipendenti (ESPP) 2021. Questa azione segue la chiusura della fusione del 23 luglio 2025 con Concentra Biosciences, dopo la quale Elevation 猫 diventata una controllata interamente posseduta e le sue offerte pubbliche sono cessate.
In base alla fusione, ogni azione ordinaria 猫 stata convertita in 0,36 $ in contanti pi霉 un diritto contingente di valore non trasferibile (CVR). Circa 14,3 milioni di azioni鈥攃irca 9,7 milioni sotto il Piano 2021, 1,7 milioni sotto l'ESPP e 2,4 milioni sotto il Piano 2019鈥攕ono state ritirate dalla registrazione. La presentazione elimina qualsiasi futura emissione di azioni da questi piani e conclude formalmente gli obblighi di rendicontazione S-8 della societ脿.
Elevation Oncology (ELEV) present贸 cinco Enmiendas Post-Efectivas a declaraciones de registro Form S-8 previas para cancelar la inscripci贸n de todas las acciones no vendidas relacionadas con su Plan de Incentivos de Acciones 2019, Plan de Incentivos de Acciones 2021 y Plan de Compra de Acciones para Empleados (ESPP) 2021. Esta acci贸n sigue al cierre de la fusi贸n el 23 de julio de 2025 con Concentra Biosciences, tras lo cual Elevation se convirti贸 en una subsidiaria de propiedad total y cesaron sus ofertas p煤blicas.
Bajo la fusi贸n, cada acci贸n com煤n se convirti贸 en
Elevation Oncology (ELEV)電� 2019雲� 欤检嫕 鞚胳劶韹半笇 頂岆灉, 2021雲� 欤检嫕 鞚胳劶韹半笇 頂岆灉 氚� 2021雲� ESPP鞕� 甏�霠悳 氙疙寪毵� 欤检嫕 鞝勲秬毳� 霌彪 毵愳唽頃橁赴 鞙勴暣 鞚挫爠 Form S-8 霌彪 鞁犼碃靹滌棎 雽�頃� 雼れ劘 瓯挫潣 靷泟 須牓 靾橃爼靹滊ゼ 鞝滌稖頄堨姷雼堧嫟. 鞚� 臁办箻電� 2025雲� 7鞗� 23鞚� Concentra Biosciences鞕�鞚� 頃╇硲 膦呺鞐� 霐半ジ 瓴冹溂搿�, 鞚错泟 Elevation鞚� 鞕勳爠 鞛愴殞靷 鞝勴櫂霅橃柎 瓿店皽 欤检嫕 氚滍枆鞚� 欷戨嫧霅橃棃鞀惦媹雼�.
頃╇硲鞐� 霐半澕 氤错喌欤茧姅 欤茧嫻 順勱笀 0.36雼煬鞕� 鞏戨弰 攵堦皜電ロ暅 臁瓣贝攵� 臧�旃� 甓岆Μ(CVR) 1臧�搿� 鞝勴櫂霅橃棃鞀惦媹雼�. 鞎� 1,430毵� 欤�鈥�2021雲� 頂岆灉鞐愳劀 鞎� 970毵� 欤�, ESPP鞐愳劀 170毵� 欤�, 2019雲� 頂岆灉鞐愳劀 240毵� 欤尖�旉皜 霌彪鞐愳劀 觳犿殞霅橁碃 鞛堨姷雼堧嫟. 鞚措矆 鞝滌稖搿� 鞚措摛 頂岆灉鞐愳劀鞚� 頄ロ泟 欤检嫕 氚滍枆鞚� 欷戨嫧霅橁碃 須岇偓鞚� S-8 氤搓碃 鞚橂臧� 瓿奠嫕鞝侅溂搿� 膦呺霅╇媹雼�.
Elevation Oncology (ELEV) a d茅pos茅 cinq amendements post-efficacit茅 aux d茅clarations d鈥檈nregistrement Form S-8 ant茅rieures afin de d茅r茅f茅rencer toutes les actions invendues li茅es 脿 son Plan d鈥橧ncentive Actions 2019, au Plan d鈥橧ncentive Actions 2021 et au Plan d鈥橝chat d鈥橝ctions des Employ茅s (ESPP) 2021. Cette d茅marche fait suite 脿 la cl么ture de la fusion le 23 juillet 2025 avec Concentra Biosciences, apr猫s laquelle Elevation est devenue une filiale en propri茅t茅 exclusive et ses offres publiques ont cess茅.
Dans le cadre de la fusion, chaque action ordinaire a 茅t茅 convertie en 0,36 $ en esp猫ces plus un droit de valeur conditionnel non transf茅rable (CVR). Environ 14,3 millions d鈥檃ctions鈥攅nviron 9,7 millions sous le Plan 2021, 1,7 million sous l鈥橢SPP et 2,4 millions sous le Plan 2019鈥攕ont retir茅es de l鈥檈nregistrement. Ce d茅p么t supprime toute 茅mission future d鈥檃ctions issues de ces plans et met officiellement fin aux obligations de reporting S-8 de la soci茅t茅.
Elevation Oncology (ELEV) hat f眉nf Nachwirkende 脛nderungen zu fr眉heren Form S-8-Registrierungserkl盲rungen eingereicht, um alle unver盲u脽erten Aktien im Zusammenhang mit dem Aktienanreizplan 2019, dem Aktienanreizplan 2021 und dem Aktienkaufplan f眉r Mitarbeiter (ESPP) 2021 abzumelden. Dieser Schritt folgt auf den Abschluss der Fusion am 23. Juli 2025 mit Concentra Biosciences, nach der Elevation eine hundertprozentige Tochtergesellschaft wurde und 枚ffentliche Angebote eingestellt wurden.
Im Rahmen der Fusion wurde jede Stammaktie in 0,36 $ in bar plus ein nicht 眉bertragbares bedingtes Wertrecht (CVR) umgewandelt. Etwa 14,3 Millionen Aktien鈥攄avon etwa 9,7 Mio. unter dem 2021er Plan, 1,7 Mio. unter dem ESPP und 2,4 Mio. unter dem 2019er Plan鈥攚erden aus der Registrierung zur眉ckgezogen. Die Einreichung verhindert k眉nftige Aktienausgaben aus diesen Pl盲nen und beendet formell die S-8-Berichtspflichten des Unternehmens.
FAQ
Why is Elevation Oncology (ELEV) filing Post-Effective Amendments to Form S-8?
How many shares are being deregistered by ELEV?
What did shareholders receive in the Concentra merger?
Does the filing affect Elevation Oncology鈥檚 public listing?
What happens to employee stock options and ESPP shares?
